Brad Roadcap

812 total citations
16 papers, 556 citations indexed

About

Brad Roadcap is a scholar working on Epidemiology, Immunology and Surgery. According to data from OpenAlex, Brad Roadcap has authored 16 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Epidemiology, 4 papers in Immunology and 3 papers in Surgery. Recurrent topics in Brad Roadcap's work include Respiratory viral infections research (4 papers), Pneumonia and Respiratory Infections (3 papers) and Computational Drug Discovery Methods (3 papers). Brad Roadcap is often cited by papers focused on Respiratory viral infections research (4 papers), Pneumonia and Respiratory Infections (3 papers) and Computational Drug Discovery Methods (3 papers). Brad Roadcap collaborates with scholars based in United States, Netherlands and Italy. Brad Roadcap's co-authors include Jamie J. Zhao, Lida Liu, Thomayant Prueksaritanont, Bennett Ma, John Rogers, Paul G. Pearson, Jiunn H. Lin, Thomas A. Baillie, Cuyue Tang and Yue Qiu and has published in prestigious journals such as The Journal of Infectious Diseases, Journal of Pharmacology and Experimental Therapeutics and Journal of Pharmaceutical Sciences.

In The Last Decade

Brad Roadcap

16 papers receiving 536 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brad Roadcap United States 12 235 139 97 97 91 16 556
Raju D. Amin United States 13 262 1.1× 72 0.5× 35 0.4× 167 1.7× 108 1.2× 16 809
Gangadhar Sunkara United States 22 151 0.6× 237 1.7× 84 0.9× 117 1.2× 184 2.0× 71 1.0k
Ali Raza United States 10 553 2.4× 163 1.2× 57 0.6× 66 0.7× 103 1.1× 30 812
Donald M. Gibson United States 12 250 1.1× 58 0.4× 49 0.5× 70 0.7× 83 0.9× 17 671
Julie Zalikowski United States 6 287 1.2× 82 0.6× 32 0.3× 116 1.2× 169 1.9× 7 516
Ian Holmes United States 13 298 1.3× 50 0.4× 52 0.5× 79 0.8× 80 0.9× 34 609
Ying‐Fu Chen Taiwan 12 230 1.0× 188 1.4× 35 0.4× 339 3.5× 102 1.1× 41 851
Mike J. Warwick United Kingdom 12 485 2.1× 105 0.8× 81 0.8× 200 2.1× 247 2.7× 14 873
Francis Heitz Switzerland 8 164 0.7× 68 0.5× 60 0.6× 207 2.1× 213 2.3× 8 855
Dietmar Ganßer Germany 19 162 0.7× 58 0.4× 106 1.1× 147 1.5× 267 2.9× 30 1.9k

Countries citing papers authored by Brad Roadcap

Since Specialization
Citations

This map shows the geographic impact of Brad Roadcap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Roadcap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Roadcap more than expected).

Fields of papers citing papers by Brad Roadcap

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Roadcap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Roadcap. The network helps show where Brad Roadcap may publish in the future.

Co-authorship network of co-authors of Brad Roadcap

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Roadcap. A scholar is included among the top collaborators of Brad Roadcap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Roadcap. Brad Roadcap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Sinha, Anushua, Radha Railkar, Luis A. Castagnini, et al.. (2025). Evaluation of a monoclonal antibody against respiratory syncytial virus, clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemporary Clinical Trials. 157. 107995–107995. 3 indexed citations
2.
Madhi, Shabir A., Eric A. F. Simões, Radha Railkar, et al.. (2024). A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. The Journal of Infectious Diseases. 231(3). e478–e487. 17 indexed citations
3.
Phuah, Jia Yao, Brian M. Maas, Aimin Tang, et al.. (2023). Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomedicine & Pharmacotherapy. 169. 115851–115851. 22 indexed citations
4.
Anderson, Melanie, Marissa F. Dockendorf, Ian McIntosh, et al.. (2022). An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat. The AAPS Journal. 24(3). 52–52. 3 indexed citations
5.
6.
Roadcap, Brad, Azher Hussain, Yang Xu, et al.. (2020). Clinical Application of Volumetric Absorptive Microsampling to the Gefapixant Development Program. Bioanalysis. 12(13). 893–904. 20 indexed citations
7.
Aliprantis, Antonios O., Luzelena Caro, Brian M. Maas, et al.. (2020). A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults. Clinical Pharmacology in Drug Development. 10(5). 556–566. 47 indexed citations
8.
Roadcap, Brad, et al.. (2019). Determination of Doravirine in Human Plasma Using Liquid–liquid Extraction and HPLC–MS/MS. Bioanalysis. 11(16). 1495–1508. 11 indexed citations
9.
Mitra, Amitava, Brad Roadcap, Christine Mestre, et al.. (2015). Use of Minipig Skin Biopsy Model as an Innovative Tool to Design Topical Formulation to Achieve Desired Pharmacokinetics in Humans. Journal of Pharmaceutical Sciences. 104(5). 1701–1708. 12 indexed citations
10.
Bergman, Arthur, Josée Côté, Andrea Maes, et al.. (2009). Effect of Sitagliptin on the Pharmacokinetics of Simvastatin. The Journal of Clinical Pharmacology. 49(4). 483–488. 29 indexed citations
11.
Krishna, Rajesh, Arthur Bergman, Bo Jin, et al.. (2008). Assessment of the CYP3A‐Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology. 49(1). 80–87. 31 indexed citations
12.
Bergman, Arthur, J Côté, A. Maes, et al.. (2006). PII-46Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans. Clinical Pharmacology & Therapeutics. 79(2). P48–P48. 7 indexed citations
13.
14.
Prueksaritanont, Thomayant, Jamie J. Zhao, Bennett Ma, et al.. (2002). Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins. Journal of Pharmacology and Experimental Therapeutics. 301(3). 1042–1051. 219 indexed citations
15.
Prueksaritanont, Thomayant, José María Guerrero Vega, Jamie J. Zhao, et al.. (2001). Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. The Journal of Clinical Pharmacology. 41(5). 573–581. 47 indexed citations
16.
Zhao, Jamie J., et al.. (2000). Quantitation of simvastatin and its ?-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. Journal of Mass Spectrometry. 35(9). 1133–1143. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raju D. Amin Breakdown of academic impact, for papers by Gangadhar Sunkara Breakdown of academic impact, for papers by Ali Raza Breakdown of academic impact, for papers by Donald M. Gibson Breakdown of academic impact, for papers by Julie Zalikowski Breakdown of academic impact, for papers by Ian Holmes Breakdown of academic impact, for papers by Ying‐Fu Chen Breakdown of academic impact, for papers by Mike J. Warwick Breakdown of academic impact, for papers by Francis Heitz Breakdown of academic impact, for papers by Dietmar Ganßer
Rankless by CCL
2026